Krystal Biotech (KRYS) Stock Forecast & Price Target

Compare

630 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KRYS Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Krystal

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KRYS Stock 12 Month Forecast

Average Price Target

$328.78

▲(16.06% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $328.78 with a high forecast of $371.00 and a low forecast of $295.00. The average price target represents a 16.06% change from the last price of $283.29.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","186":"$186","248":"$248","310":"$310","372":"$372"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":371,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$371.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":328.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$328.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$295.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,186,248,310,372],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282.27,289.0953846153846,295.9207692307692,302.74615384615385,309.57153846153847,316.3969230769231,323.2223076923077,330.0476923076923,336.8730769230769,343.6984615384615,350.52384615384614,357.34923076923076,364.1746153846154,{"y":371,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282.27,285.8476923076923,289.4253846153846,293.0030769230769,296.5807692307692,300.1584615384615,303.7361538461538,307.31384615384616,310.89153846153846,314.46923076923076,318.04692307692306,321.62461538461537,325.20230769230767,{"y":328.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282.27,283.24923076923073,284.22846153846154,285.2076923076923,286.18692307692305,287.16615384615386,288.1453846153846,289.12461538461537,290.1038461538461,291.08307692307693,292.0623076923077,293.04153846153844,294.02076923076925,{"y":295,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":282.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$371.00

Average Price Target$328.78

Lowest Price Target$295.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geulah Livshits

Chardan Capital

$220→$323

Buy

14.02%

Upside

Reiterated

02/18/26

Krystal Biotech price target raised to $323 from $220 at ChardanKrystal Biotech price target raised to $323 from $220 at Chardan

Joseph Pantginis

H.C. Wainwright

$310

Buy

9.43%

Upside

Reiterated

02/18/26

Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages

Ritu Baral

TD Cowen

$306

Buy

8.02%

Upside

Reiterated

02/17/26

Krystal Biotech: Strong Vyjuvek Momentum, Robust Balance Sheet, and Late-Stage Pipeline Upside Support Buy Rating

Sami Corwin

William Blair

Buy

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Cogent Biosciences (NASDAQ: COGT)

Alec Stranahan

Bank of America Securities

$318

Buy

12.25%

Upside

Reiterated

02/17/26

Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target

Yigal Nochomovitz

Citi

$336→$371

Buy

30.96%

Upside

Reiterated

02/17/26

Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline

Roger Song

Jefferies

$371

Buy

30.96%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Medtronic (NYSE: MDT)

Andrea Tan

Goldman Sachs

$206→$327

Buy

15.43%

Upside

Reiterated

01/30/26

Krystal Biotech price target raised to $327 from $206 at Goldman SachsKrystal Biotech price target raised to $327 from $206 at Goldman Sachs

William Maughan

Clear Street

$288→$338

Buy

19.31%

Upside

Reiterated

01/26/26

Krystal Biotech price target raised to $338 from $288 at Clear StreetKrystal Biotech price target raised to $338 from $288 at Clear Street

Gavin Clark-Gartner

Evercore ISI

$278→$295

Buy

4.13%

Upside

Reiterated

01/09/26

Debjit Chattopadhyay

Guggenheim

$189→$224

Buy

-20.93%

Downside

Reiterated

10/16/25

Krystal Biotech price target raised to $224 from $189 at GuggenheimKrystal Biotech price target raised to $224 from $189 at Guggenheim

Joshua Schimmer

Cantor Fitzgerald

$215

Buy

-24.11%

Downside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geulah Livshits

Chardan Capital

$220→$323

Buy

14.02%

Upside

Reiterated

02/18/26

Krystal Biotech price target raised to $323 from $220 at ChardanKrystal Biotech price target raised to $323 from $220 at Chardan

Joseph Pantginis

H.C. Wainwright

$310

Buy

9.43%

Upside

Reiterated

02/18/26

Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages

Ritu Baral

TD Cowen

$306

Buy

8.02%

Upside

Reiterated

02/17/26

Krystal Biotech: Strong Vyjuvek Momentum, Robust Balance Sheet, and Late-Stage Pipeline Upside Support Buy Rating

Sami Corwin

William Blair

Buy

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Cogent Biosciences (NASDAQ: COGT)

Alec Stranahan

Bank of America Securities

$318

Buy

12.25%

Upside

Reiterated

02/17/26

Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target

Yigal Nochomovitz

Citi

$336→$371

Buy

30.96%

Upside

Reiterated

02/17/26

Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline

Roger Song

Jefferies

$371

Buy

30.96%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Medtronic (NYSE: MDT)

Andrea Tan

Goldman Sachs

$206→$327

Buy

15.43%

Upside

Reiterated

01/30/26

Krystal Biotech price target raised to $327 from $206 at Goldman SachsKrystal Biotech price target raised to $327 from $206 at Goldman Sachs

William Maughan

Clear Street

$288→$338

Buy

19.31%

Upside

Reiterated

01/26/26

Krystal Biotech price target raised to $338 from $288 at Clear StreetKrystal Biotech price target raised to $338 from $288 at Clear Street

Gavin Clark-Gartner

Evercore ISI

$278→$295

Buy

4.13%

Upside

Reiterated

01/09/26

Debjit Chattopadhyay

Guggenheim

$189→$224

Buy

-20.93%

Downside

Reiterated

10/16/25

Krystal Biotech price target raised to $224 from $189 at GuggenheimKrystal Biotech price target raised to $224 from $189 at Guggenheim

Joshua Schimmer

Cantor Fitzgerald

$215

Buy

-24.11%

Downside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+13.55%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +13.55% per trade.

1 Year

Sami CorwinWilliam Blair

Success Rate

11/11 ratings generated profit

Average Return

+55.44%

reiterated a buy rating last month

Copying Sami Corwin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.44% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+96.18%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +96.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRYS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KRYS has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KRYS average Analyst price target in the past 3 months is 328.78.

Each month's total comprises the sum of three months' worth of ratings.

KRYS Financial Forecast

KRYS Earnings Forecast

Next quarter’s earnings estimate for KRYS is $1.46 with a range of $1.27 to $2.12. The previous quarter’s EPS was $1.70. KRYS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.

KRYS Sales Forecast

Next quarter’s sales forecast for KRYS is $111.59M with a range of $105.93M to $120.10M. The previous quarter’s sales results were $107.11M. KRYS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year KRYS has Performed in-line its overall industry.

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?

Based on analyst ratings, Krystal Biotech’s 12-month average price target is 328.78.

What is KRYS’s upside potential, based on the analysts’ average price target?

Krystal Biotech has 16.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KRYS a Buy, Sell or Hold?

Krystal Biotech has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Krystal Biotech’s price target?

The average price target for Krystal Biotech is 328.78. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $371.00 ,the lowest forecast is $295.00. The average price target represents 16.06% Increase from the current price of $283.29.

What do analysts say about Krystal Biotech?

Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of KRYS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Krystal Biotech (KRYS) Stock Forecast & Price Target

KRYS Analyst Ratings

KRYS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Krystal Biotech

KRYS Analyst Recommendation Trends

KRYS Financial Forecast

KRYS Earnings Forecast

KRYS Sales Forecast

KRYS Stock Forecast FAQ

Detailed List of Analyst Forecasts